1. United States Securities Exchange Commission, Form S-1 filed by Eagle Pharmaceuticals, Inc. on Dec 20, 2013. www.sec.gov​/Archives/edgar​/data/827871​/000104746913011312​/a2217789zs-1.htm.
  2. The Joint Commission Report; Standards BoosterPak for MM.03.01.01. Updated March 2013.
  3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172-1193.
  4. American Society of Health-System Pharmacists. Practice Basics. Chapter 17: Medication Errors. www.ashp.org/DocLibrary/Bookstore/P2074/Chpt-17.aspx. 2010. Accessed September 2, 2015.
  5. Lose JM, Dorsch MP, Stevenson, JG. Cost Containment for Argatroban Through Reduction in Drug Waste: Experience of a Single Center. Pharmacy Times, March 2013. Supplement 1-4.
  6. Dantrium Intravenous [package insert]. Rochester, MI: JHP Pharmaceuticals, LLC; 2008.
  7. Revonto [package insert]. Louisville, KY: US WorldMeds, LLC; 2011.
  8. Argatroban Injection [package insert]. Parsippany, NJ: The Medicines Company; 2014.
  9. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014.
  10. Data on file. Eagle Pharmaceuticals, Inc.
  11. Brandom BW. Cases from the North American MH Registry/MHAUS [1992 through 2012].
  12. Malignant Hyperthermia Association of the United States. Managing an MH crisis. www.mhaus.org​/healthcare-professionals​/managing-a-crisis. Accessed November 17, 2015.
  13. Diclofenac sodium and misoprostol delayed-release tablets [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2013.
  14. Argatroban Injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.